Sandoz Will Appeal Against US Enbrel Patent Setback

 
• By Aidan Fry

Sandoz expects to bring an expedited appeal against a US district court’s finding that two patents protecting Amgen’s Enbrel etanercept brand until 2028 and 2029 are valid. 

Signpost_2029
Sandoz could be barred from launching its Erelzi biosimilar etanercept in the US until 2029 following an adverse district court ruling • Source: Shutterstock

More from Biosimilars

More from Products